Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syntara Limited ( (AU:SNT) ) has shared an update.
Syntara Limited announced a webinar featuring key opinion leader Professor Ardeshir Bayat to discuss the treatment landscape for skin scarring and provide updates on their drug SNT-9465. SNT-9465, a topical anti-fibrotic drug, is currently in Phase 1 clinical trials and aims to address the unmet need for effective treatments for hypertrophic scars, potentially becoming the first approved pharmacological treatment in this area.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company specializing in extracellular matrix dysfunction. They leverage expertise in amine oxidase chemistry to develop novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, targets myelofibrosis, and they are advancing other candidates for various fibrotic and inflammatory diseases.
Average Trading Volume: 2,536,417
Technical Sentiment Signal: Sell
Current Market Cap: A$47.34M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.